New drug combo aims to slow kidney disease
NCT ID NCT06221059
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 trial tested two drugs, HRS-1780 and henagliflozin, in 181 adults with chronic kidney disease. Participants took the drugs or placebos for 13 weeks to see if the drugs could reduce protein in the urine, a sign of kidney damage. The study aimed to find a new way to help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-1780 tablet and henagliflozin proline tablet
- What this could lead to
- If successful, this could point toward a new treatment option to slow kidney damage in chronic kidney disease patients.
- What could go wrong
- This is an early Phase 2 trial with only 181 participants, so results may not apply to everyone. The drugs may not show meaningful benefit over placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
General Hospital of Eastern Theater Command
Nanjing, Jiangsu, 210002, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk